Clinical Trials Directory

Trials / Completed

CompletedNCT02064114

SORT - AF Supervised Obesity Reduction Trial for AF Ablation Patients

Supervised Obesity Reduction Trial for AF Ablation Patients

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
142 (actual)
Sponsor
Universitätsklinikum Hamburg-Eppendorf · Academic / Other
Sex
All
Age
18 Years – 80 Years
Healthy volunteers
Not accepted

Summary

Study hypothesis: Weight reduction in obese patients with atrial fibrillation. Obese patients benefit from an obesity treatment after atrial fibrillation ablation. Study design: A prospective randomized, open-label clinical trial.

Detailed description

Study protocol: The purpose of this study is to proof a professional care of overweight patients with symptomatic atrial fibrillation, as well as the treatment of the risk factors for atrial fibrillation, especially obstructive sleep apnea and hypertension. There is a 1:1 randomization. In the intervention group, patients are followed up in a 6-month intensive care after atrial fibrillation ablation. During the follow up time patients will visit the nutritional advice every two weeks for 6 months. The Follow-up in the control group is standard of care. At baseline, a screening test for obstructive sleep apnea and arterial hypertension will be performed as standard care. The documentation of atrial fibrillation after ablation is made possible by the implantation of an event recorder before atrial fibrillation ablation. Follow up: A follow-up will be performed after 3,6 and 12 months in both groups. Patients in the intervention group will be followed-up every 2 weeks in the first 6 months.

Conditions

Interventions

TypeNameDescription
PROCEDUREIntervention groupStart of optimal management of risk factors, every 2 weeks for 6 months after atrial fibrillation ablation. And followed for a period of 3,6 and 12 months after the procedure.
PROCEDUREcontrol groupFollowed for a period of 3,6 and 12 months after the procedure.

Timeline

Start date
2014-01-01
Primary completion
2020-01-16
Completion
2020-01-16
First posted
2014-02-17
Last updated
2022-09-19

Locations

4 sites across 1 country: Germany

Source: ClinicalTrials.gov record NCT02064114. Inclusion in this directory is not an endorsement.